Kornimate/medical-research-clean huggingface dataset:
the effects of rtms and tdcs combined with robotic rehabilitation in patients with spinal cord injury

Conditions: Chronic Spinal Cord Disorder

Summary: the purpose of this study is to assess the effect of rtms and tdcs combined with robotic therapy on motor functional recovery and gait parameters

after being informed about study and potential risks, all patient giving written informed consent will undergo screening period determine eligibility for study entry. the patients who meet the eligibility requirements will be randomized into four groups in a 1:1 ratio to active rtms, sham rtms, active tdcs and sham tdcs.

Eligibility criteria:
inclusion criteria: * having traumatic sci * between 6 months and 2 years after sci * 18-65 years old * signing an informed consent form showing his/her consent to participate in the study. * motor incomplete cervical or thoracic sci * spasticity in the lower extremity ≤2 according to the modified ashworth scale exclusion criteria: * history of epilepsy * a cardiac pacemaker * pregnancy * neurological diseases other than sci * metallic implant in brain or scalp (including cochlear implant) * previous brain surgery * orthopedic disease that prevents lower extremity movements * diagnosis of malignancy * receiving robotic /tms/tdcs treatments in the last 6 months
use of low-cost mhealth intervention to enhance outcomes of noncommunicable diseases care in rural and refugee settings

Conditions: Diabetes Mellitus; Hypertension

Summary: rural areas and refugee camps are characterized by poor access of patients to needed noncommunicable disease (ncd)-related health services, including diabetes and hypertension. this community trial study aims to assess the effect of employing low-cost mhealth tools on the accessibility to health services and improvement of health indicators of individuals with ncds in rural areas and refugee camps in lebanon.

rural areas and refugee camps are characterized by poor access of patients to needed noncommunicable disease (ncd)-related health services, including diabetes and hypertension. employing low-cost innovative ehealth interventions, such as mobile health (mhealth), may help improve ncds prevention and control among disadvantaged populations. the aim of this study was to assess the effect of employing low-cost mhealth tools on the accessibility to health services and improvement of health indicators of individuals with ncds in rural areas and refugee camps in lebanon. this is a community trial study in which centers were allocated randomly into control and intervention sites. the effect of an employed mhealth intervention is assessed through selected quality indicators examined in both control and intervention groups. sixteen primary health care centers (eight controls, eight interventions) located in rural areas and palestinian refugee camps across lebanon were included in this study. data on diabetic and hypertensive patients-1433 in the intervention group and 926 in the control group-was extracted from patient files in the pre and postintervention periods. the intervention entailed weekly short message service messages, including medical information, importance of compliance, and reminders of appointments or regular physician follow-up. internationally established care indicators were utilized in this study.

Eligibility criteria:
inclusion criteria: * registered at the primary healthcare center as diabetics and/or hypertensive or diagnosed with or suspected to have diabetes and/or hypertension * aged 40 years or more * lebanese or palestinian nationality exclusion criteria: * aged less than 40 years * non-lebanese / non-palestinian * no exclusion based on gender, educational and literacy level, disability, or presence of other medical conditions

Keywords: noncommunicable diseases hypertension diabetes mellitus telemedicine mobile health rural health refugees
comparison of using regular or rotary polypectomy snare for the resection of colorectal polyps

Conditions: Polypectomy Snare

Summary: this clinical trial is being conducted to assess whether the rotary polypectomy snare could decrease the time to removal of colorectal polyps


Eligibility criteria:
inclusion criteria: 18-85 year; patients with colorectal polyps ; informed consent; exclusion criteria: patients taking antiplatelet or anticoagulant therapy during the past 1 week of the procedure; known coagulopathy; history of inﬂammatory bowel diseases; hemodynamically unstable; pregnancy
correlation between esophageal temperature and skin temperature in trauma patients

Conditions: Core Temperature; Trauma

Summary: the goal of this retrospective data-based study is to investigate the correlation between esophageal temperature and skin core temperature in trauma patients who underwent emergency surgery. based on the medical records of patients who applied both temperature measurements simultaneously, the correlation between the skin core temperature and the esophageal temperature was investigated

hypothermia is known to be one of the factors that increase mortality rate in trauma patients. therefore it is important to measure and manage the core temperature in trauma patients. esophageal temperature is common method to measure core temperature in patients undergoing surgery under general anesthesia. however, it is not applicable in patients who have not been intubated or in patients with suspected esophageal damage. in addition, esophageal temperature probe is twisted in the mouth and does not reflect core temperature properly. 3m™ bair hugger™ temperature monitoring system was developed to measure the core temperature by attaching to the skin using zero heat flow mechanism. it is simple to apply, and available at the trauma scene. previous studies have reported that skin core temperature reflects core temperature well, but no studies have been conducted on trauma patients with rapid changes in the core temperature and poor perfusion state. this retrospective data-based study investigate the medical records of trauma patients who underwent emergency surgery. patients who applied two temperature measurements at the same time were targeted. since this center has the system that automatically transfer the hemodynamic data of the monitor to the anesthesia record, the investigators use the anesthesia records.

Eligibility criteria:
inclusion criteria: * trauma patients who underwent emergency surgery from january 1, 2021 to october 31, 2021 * who applied both a esophageal thermometer and a 3m™ bair hugger™ temperature monitoring system at the same time exclusion criteria: * when more than half of the data is missing
imiquimod plus antimony immunochemotherapy for cutaneous leishmaniasis

Conditions: Cutaneous Leishmaniasis

Summary: this study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis. based on our previous results, we hypothesize that lesions in patients who receive the combined treatment of pentavalent antimony and imiquimod as a first line therapy will resolve more rapidly and produce less scarring than treatment with pentavalent antimony alone.


Eligibility criteria:
inclusion criteria: * males/females between 5 and 65 yrs * cl diagnosis confirmed * \>4 weeks time disease * no prior anti-leishmanial therapy for cl * negative pregnancy test * informed written consent or parent consent for \<18yrs patients exclusion criteria: * \>25cm2 lesion(s) * \>6 cutaneous lesions * mucosal lesion * previous exposure to imiquimod or anti-leish treatment * participation in another protocol within 30 days prior study * other acute or chronic illness / medication that may interfere * significant psychiatric illness * anaphylaxis or severe allergic reaction to proposed drugs * patients unlikely to cooperate * concomitant infection * pregnancy or breast feeding
emergency use of ocr-002 in acute liver failure (alf)

Conditions: Acute Liver Failure

Summary: this study provides emergency use of the unapproved study medication in alf patients with acute liver failure who are not responding to standard of care.

this is an open-label study in patients diagnosed with alf who are not responding to the institution's standards of care. standard of care may include, but is not limited to, administration of n-acetylcysteine, lactulose, hypothermia therapy, and consideration for orthotopic liver transplant.

Eligibility criteria:
inclusion criteria: * international normalized ratio (inr) ≥1.5 with encephalopathy in patient with no prior history of liver disease * venous ammonia level of ≥ 100 μmol/l exclusion criteria: * patients who are pregnant
the use of music in reducing pain during outpatient hysteroscopy

Conditions: Hysteroscopy

Summary: the aim of this study is to demonstrate the value of music in outpatient hysteroscopy on patients' level of pain and satisfaction. this may have a role in our daily practice in providing a better patient care in outpatient hysteroscopy.

outpatient hysteroscopy is nowadays a commonly used procedure in gynaecology in order to evaluate the uterine cavity and to diagnose different intrauterine diseases. it is a safe, convenient and cost-effective procedure in aiding the management of abnormal uterine bleeding. however, outpatient hysteroscopy can be associated with significant pain which would have impact on the woman's satisfaction and pain is one of the most common reasons for failure of the procedure. listening to music could be an easy and non-invasive way to reduce pain. a meta-analysis conducted on the effects of music on pain revealed that music interventions had statistically significant effects in decreasing pain on 0-10 pain scales. researches on this topic in gynaecological office procedures, however, showed variation in the results. some showed no positive effect of music on patient's level of pain, anxiety or satisfaction of patient or doctor for office hysteroscopy and colposcopy. on the other hand, some studies showed a positive effect of the use of music with a reduction of pain and anxiety during office hysteroscopy.

Eligibility criteria:
inclusion criteria: * indication for hysteroscopy (abnormal uterine bleeding, abnormal findings on ultrasound, and infertility) * signed informed consent * ability to read chinese or english. exclusion criteria: * hearing impairment * known anatomical abnormalities which would make performing the procedure more difficult * use of premedication for cervical ripening
contamination of bacillus species sepsis.

Conditions: Bacillus Cereus Infection

Summary: bacillus species are ubiquitous gram-positive spore-forming organisms. they rarely cause disease in the immunocompetent and are more frequently isolated as a culture contaminant. however, bacillus species can cause severe systemic infections in immunocompromised patients including preterm infants. the purpose of this study is to identify the risk factors of these infections.

non-anthrax bacillus species bacteria can be responsible for food poisoning and local infections. rarely, they lead to severe infections like blood stream infections and meningitis especially in immunocompromised patients like preterm infants. bacillus cereus is the most common members of the genus bacillus. only few reports studied these systemic infections in premature neonates. in order to identify the risk factors for severe bacillus species infections, we studied retrospectively eleven cases of these infections in our nicu and reviewed series and report cases in literature.

Eligibility criteria:
inclusion criteria: * cases of bacillus species sepsis * cases of bacillus species meningitis * with significant change in clinical status * bacillus species is the only organism isolated exclusion criteria: * bacillus species isolated with other organisms and bacillus species without clinical change were considered to be contaminants

Keywords: bacillus cereus premature neonates
smoking and peptidoglycan recognition protein-1 and initial periodontal therapy

Conditions: Smoking, Cigarette

Summary: a total of 40 patients with cp (20 smokers (s+cp) and 20 nonsmokers (s-cp)) and 40 periodontally healthy subjects (20 smokers (s+ph) and 20 nonsmokers (s-ph)), comprising 80 subjects, were included in this study. baseline gcf samples were obtained from all subjects and clinical periodontal measurements, including probing depth (pd), clinical attachment level (cal), plaque index (pi), and gingival index (gi), were recorded. in patients who had received initial periodontal therapy, gcf samples were obtained and all clinical periodontal measurements were recorded again during the 6th-8th weeks. gcf pgrp-1 levels were analyzed by enzyme-linked immunosorbent assay.

peptidoglycan recognition proteins (pgrps) are one of the antimicrobial peptides that play a role in innate immunity and act against the bacterial cell wall. smoking is the most important environmental risk factor for periodontitis. this study determined the effect of smoking on pgrp-1 levels in gingival crevicular fluid (gcf) in smokers and nonsmokers with chronic periodontitis (cp) following initial periodontal therapy.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of severe chronic periodontitis * clinical diagnosis of periodontal health exclusion criteria: * have any systemic disease, * to be alcohol consumer, * to receive any periodontal therapy in the past 6 months, * to take any drugs regularly * to be pregnant and/or lactate.

Keywords: chronic periodontitis gingival crevicular fluid initial periodontal therapy peptidoglycan recognition proteins smoking
ledipasvir/sofosbuvir fixed-dose combination + ribavirin in subjects with chronic hcv with advanced liver disease or post-liver transplant

Conditions: Chronic HCV Infection

Summary: this study will evaluate ledipasvir/sofosbuvir (ldv/sof) fixed-dose combination (fdc) plus ribavirin (rbv) in participants with advanced liver disease or posttransplant and chronic genotype 1 or 4 hepatitis c virus (hcv) infection. * cohort a: decompensated cirrhosis (advanced liver disease), no prior liver transplant; * cohort b: post-liver transplant, with or without cirrhosis; * group assignment within cohorts is based on severity of liver impairment at screening (child-pugh-turcotte (cpt) score for participants with cirrhosis; fibrosis; or presence of disease for fibrosing cholestatic hepatitis (fch) groups) * randomization is 1:1 within groups to 12 or 24 weeks of ldv/sof+rbv treatment.


Eligibility criteria:
inclusion criteria: * able to provide written informed consent * chronic genotype 1 or 4 hcv infection * normal ecg * negative serum pregnancy test for female subjects * male subjects and female subjects of childbearing potential must agree to use contraception * able to comply with the dosing instructions for study drug and able to complete the study schedule of assessments, including all required post treatment visits exclusion criteria: * serious or active medical or psychiatric illness * hiv or hepatitis b viral (hbv) infection * stomach disorder that could interfere with the absorption of the study drug * treated with an anti-hcv medication in the last 30 days * any prior exposure to an hcv nonstructural protein (ns)5a-specific inhibitor * use of human granulocyte-macrophage colony-stimulating factor (gm-csf), epoetin alfa or other therapeutic hematopoietic agents within 2 weeks of screening * history of clinically significant medical condition associated with other chronic liver disease * active spontaneous bacterial peritonitis at screening * females who are breastfeeding * infection requiring systemic antibiotics * participated in a clinical study with an investigational drug or biologic within the last 30 days * active or history (last 6 months) of drug or alcohol abuse * history of organ transplant other than liver or kidney
autologous mesenchymal stem cell transplant for parkinson's disease

Conditions: Parkinson's Disease

Summary: this study is intended to look at the safety and efficacy of the use of autologous bone marrow derived stem cell transplant in patients with advanced parkinson's disease.

parkinson's disease, a neurodegenerative disorder, still at its best can only be controlled by medical or surgical treatment. for more than two decades various groups have tried using modified cell transplants for curing this disease. earlier results with use of fetal mesencephalic cell transplant were encouraging, but this had to be discontinued due to severe side effects. current interest, in the use of mesenchymal stem cells as a pluripotent cell for developing neural cells has been the background for this study. reliance life sciences had found encouraging results with the use of human mscs in rat model of pd. based on this and other data, jaslok hospital and research centre has initiated a pilot study to investigate the efficacy of autologous mscs in treating advanced pd. this cells will be harvested from bone marrow, processed at rls laboratory and transplanted by stereotactic techniques into the striatum of the patient.

Eligibility criteria:
inclusion criteria * male or female between 35-70 years of age. * patient with current diagnosis of pd with motor complications (as confirmed by neurologist) as per the standard criteria and guidelines. * patients with at least 5 years since the disease. * responsiveness to levodopa or dopa agonist. this is defined as improvement between off and on updrs by at least 33% of the motor updrs. * pd of stage 2.5, 3 \& 4 of hoehn \& yahr staging. * stable parkinsonian medications for the 60 days prior to the surgical therapy. * mri not showing gross atrophy or any other pathology of brain. * patients with score less than 19 for the montgomery-asberg rating scale (madrs) for depression. * no significant cognitive impairment.mmse \> 24. * the participant is able to comply with and understand the required visit schedule and all required tests and procedures. * the participant (and/or lar) must sign an informed consent. exclusion criteria: * history of intracranial surgeries or implantation of a device for parkinson's disease two years prior to treatment. * history of psychiatric disorders like schizophrenia or psychotic disorders. * history of other malignancy, with the exception of treated cutaneous squamous cell or basal cell carcinoma, within 5 years. * contraindication for mri * general medical contraindications for surgery like coagulopathy * subjects with abnormal hematology and chemistry values, unless the out of range values are clinically significant with respect to general surgery. * severe skin infection or osteomyelitis at the site of bone marrow aspiration potentially limiting the procedure. * positive test results for hiv. * history of drug or alcohol abuse * pregnant or nursing women

Keywords: autologous stem cells.
in-use test with a cosmetic product

Conditions: Dermatitis, Atopic

Summary: the aim of the study is to evaluate the tolerance of the product wo 4260 by a dermatologist. additional objectives of this clinical in-use study are to evaluate the cosmetic features and acceptance of the product by means of a questionnaire in an interview situation and by skin hydration measurements on the scalp.


Eligibility criteria:
inclusion criteria: * age: ≥ 18 years * sex: approx. 50% male and approx. 50% female * users of hair tonic for dry scalp * dry, itchy scalp prone to atopic eczema / atopic dermatitis exclusion criteria: * any deviation from the above-mentioned criteria * users of sour hair rinse * subjects who wash their hair more than once a day * other dermatological disorders (scars, moles) on the scalp * known incompatibilities to cosmetics and ingredients of cosmetic test products (please see inci) * topical medication in the test area within 1 month prior to study start * systemic medication with anti-inflammatory agents and antibiotics within 2 weeks prior to starting of the study * systemic medication with retinoids, antihistamines and/or immunomodulators (e.g. cortisone, corticosterone, chemotherapeutic agents) within 4 weeks prior to starting of the study * systemic illness of the subject at the beginning of the study * pregnancy and period of breastfeeding

Keywords: dry scalp itchy scalp
a study of nivolumab, nivolumab plus ipilimumab, or investigator's choice chemotherapy for the treatment of participants with deficient mismatch repair (dmmr)/microsatellite instability high (msi-h) metastatic colorectal cancer (mcrc)

Conditions: Metastatic Colorectal Cancer

Summary: the main purpose of this study is to compare the clinical benefit, as measured by progression-free survival (pfs), objective response rate (orr), and overall survival (os), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) metastatic colorectal cancer (mcrc). this study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of msi-h/dmmr mcrc participants.


Eligibility criteria:
inclusion criteria: * histologically confirmed recurrent or metastatic colorectal cancer (crc) irrespective of prior treatment history with chemotherapy and/or targeted agents not amenable to surgery (applicable only during part 1 enrollment of the study) * histologically confirmed recurrent or metastatic crc with no prior treatment history with chemotherapy and/or targeted agents for metastatic disease and not amenable to surgery (applicable during part 2 enrollment of the study) * known tumor microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) status per local standard of practice * eastern cooperative oncology group (ecog) performance status lower than or equal to 1 exclusion criteria: * an active, known or suspected autoimmune disease * history of interstitial lung disease or pneumonitis * known history of positive test for human immunodeficiency virus (hiv) or known acquired immunodeficiency syndrome (aids) other protocol-defined inclusion/exclusion criteria apply
naltrexone plus ketamine for the rapid treatment of major depressive disorder and alcohol use disorder

Conditions: Major Depressive Disorder; Alcohol Use Disorder

Summary: to evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.

the primary goal of this proposal is to test naltrexone plus repeated ketamine treatment for major depressive disorder and alcohol use disorder in an open-label trial.

Eligibility criteria:
inclusion criteria: 1. male or female, 21-65 years old 2. current major depressive disorder without psychotic features by dsm-5 3. montgomery-åsberg depression rating scale (madrs) ≥ 20 4. current alcohol use disorder by dsm-5 5. heavy drinking at least 3 times in the past month ('heavy drinking' defined as ≥ 5 standard drinks per day for men and ≥ 4 standard drinks per day for women) 6. abstinence from alcohol drinking for \> 5 days prior to ketamine infusion 7. able to provide written informed consent exclusion criteria: 1. current substance use disorder by dsm-5 in the past 3 months (except alcohol, tobacco, or cannabis) 2. current or past history of psychotic features or psychotic disorder 3. current or past history of delirium or dementia 4. current uncontrolled hypertension (systolic bp \> 170 mm hg or diastolic bp \> 100 mm hg) 5. unstable medical condition or allergy to ketamine, naltrexone, or lorazepam---clinically determined by a physician 6. imminent suicidal or homicidal risk 7. pregnant or nursing women, positive pregnancy test, or inadequate birth control methods in women of childbearing potential 8. positive opioid or illicit drug screen test (except marijuana) 9. opioid use within 10 days prior to study medication (injectable naltrexone) or risks for opioid use during the study 10. liver enzymes that are three times higher than the upper limit of normal

Keywords: ketamine naltrexone depression alcohol